Hemab Therapeutics Holdings, Inc. COAG
39.86 USD +0.71 (+1.81%)
Regular-session close
39.86 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
37.91 Day range 40.03
24.98 52-week range 54.94
- YTD
- +17.24%
- 1 year
- +17.24%
News
globenewswire.com Hemab Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment…
seekingalpha.com Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript
marketbeat.com What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call Hemab Therapeutics NASDAQ: COAG has launched a pivotal Phase 3 trial of its experimental bleeding-disorder treatment sutacimig, moving its lead program into late-stage development as it prepares…
benzinga.com Hemab Therapeutics Hldgs Q3 2026 Earnings Call Transcript Hemab Therapeutics Hldgs (NASDAQ:COAG) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent.
globenewswire.com Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone Announced data showing…
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…benzinga.com LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65 LifeSci Capital initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $65.
benzinga.com Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombastheniaSingle-arm design with a 24-week run-in followed by 48 weeks…
globenewswire.com Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia Hemab's first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombastheniabenzinga.com Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today…
globenewswire.com Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial…
globenewswire.com Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026 CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment…
defenseworld.net Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $32.60, but opened at $30.82. Hemab…
defenseworld.net Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy? Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) saw strong trading volume on Wednesday. 332,235 shares were traded during trading, a decline of 11% from the previous session's…
defenseworld.net Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, Marketbeat…
globenewswire.com Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record…
globenewswire.com Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care…
defenseworld.net Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5% – Should You Buy? Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report)'s share price traded up 5.5% on Friday. The stock traded as high as $47.00 and last traded at $47.00. 17,722 shares traded hands…
seekingalpha.com Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations…
globenewswire.com Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026
benzinga.com Hemab Advances Bleeding Disorder Pipeline Hemab Therapeutics Inc. (NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003, a new program targeting heavy…
globenewswire.com Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of…
globenewswire.com Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous…
marketbeat.com Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans Hemab Therapeutics NASDAQ: COAG Chief Executive Officer Benny Sorensen outlined the company's development plans following its recent initial public offering during a fireside chat with Jefferies…
globenewswire.com Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment…
